MicroVention raises $19 million for MicroPlex launch:
This article was originally published in Clinica
MicroVention, which develops minimally invasive products for the treatment of cerebral vascular diseases, has closed a $19m round of venture capital funding. The Aliso Viejo, California-based company says the new funds will be used to support the second-quarter launch of its MicroPlex coil system and to accelerate sales and marketing of its HydroCoil embolic system for the treatment of cerebral aneurysms. Some 150,000 people are treated for cerebral aneurysms worldwide annually, with 20% undergoing an endovascular coil embolisation procedure, MicroVention says.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.